Free Trial

Gilead Sciences (GILD) Stock Price, News & Analysis

-1.12 (-1.74%)
(As of 06/18/2024 ET)
Today's Range
50-Day Range
52-Week Range
6.50 million shs
Average Volume
7.26 million shs
Market Capitalization
$78.68 billion
P/E Ratio
Dividend Yield
Price Target

Gilead Sciences MarketRank™ Stock Analysis

Analyst Rating
2.35 Rating Score
32.5% Upside
$83.69 Price Target
Short Interest
2.05% of Float Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
0.84mentions of Gilead Sciences in the last 14 days
Based on 25 Articles This Week
Insider Trading
Selling Shares
$145,920 Sold Last Quarter
Proj. Earnings Growth
From $3.75 to $7.23 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.98 out of 5 stars

Medical Sector

11th out of 913 stocks

Biological Products, Except Diagnostic Industry

3rd out of 152 stocks

GILD stock logo

About Gilead Sciences Stock (NASDAQ:GILD)

Gilead Sciences, Inc. is a leading biopharmaceutical company in Foster City, California. Founded in 1987, the company's mission is to develop innovative medicines that address unmet medical needs and improve the lives of people around the world. Gilead focuses on discovering, developing, and commercializing therapies in HIV/AIDS, liver diseases, oncology, inflammatory and respiratory diseases, and cardiovascular conditions. 

Gilead's portfolio includes a wide range of products and therapies, with its most notable product being Truvada, a leading medication for HIV prevention. The company also offers other HIV treatments, such as Biktarvy and Descovy. In addition to its HIV franchise, Gilead has significantly advanced in treating chronic hepatitis B and C with drugs like Veklury and Epclusa. Furthermore, the company has expanded into oncology with therapies such as Trodelvy and Yescarta.

Gilead Sciences is led by experienced executives who bring industry knowledge and expertise. The company's Chief Executive Officer, Daniel O'Day, joined Gilead in 2019 and has a proven track record in the pharmaceutical industry. O'Day previously served as the CEO of Roche Pharmaceuticals, where he successfully led the company through significant growth.

Gilead Sciences has consistently delivered a solid financial performance in recent years. The company has reported strong revenue and net income numbers yearly. This growth was primarily driven by solid sales of Gilead's HIV and liver disease therapies. The company averages a profit margin between 25% - 30%. Gilead has maintained a healthy balance sheet with manageable levels of debt. Gilead's strong financial position allows it to invest in research and development initiatives and pursue strategic acquisitions to drive future growth.

Investor sentiment towards Gilead has improved in recent years due to the company's strong financial performance and promising pipeline of innovative therapies. The successful launch of new products, such as Trodelvy and Biktarvy, has further bolstered investor confidence in Gilead's growth prospects.

Gilead Sciences operates in the highly competitive biopharmaceutical industry, characterized by rapid innovation, high research and development costs, and stringent regulatory requirements. The industry is subject to evolving market dynamics, including changing reimbursement policies, patent expirations, and intense competition from established and emerging biotech firms.

Gilead's expansion into oncology has been promising, with the introduction of therapies targeting specific types of cancer. However, the oncology market is highly competitive, with several significant players and emerging biotechs vying for market share. Gilead's success in this area will depend on its ability to differentiate its products, demonstrate clinical efficacy, and navigate the evolving treatment landscape.

Gilead Sciences has identified several growth opportunities that can contribute to its future success. One key focus is expanding its product portfolio through internal research and development efforts and strategic acquisitions and partnerships. By investing in innovative therapies, Gilead aims to address unmet medical needs and strengthen its competitive position.

The company's pipeline includes potential breakthrough treatments for various diseases, including novel antiviral agents, immunology candidates, and cell therapies. Gilead also explores combination therapies to enhance treatment outcomes and extend its market reach. These advancements provide opportunities for revenue growth and market expansion.

Gilead Sciences faces risks and challenges that could impact its performance and prospects. One of the primary challenges for Gilead is the potential for generic competition. As patents on some of its key products expire, there is a risk of generic manufacturers entering the market with lower-priced alternatives. This can lead to pricing pressures and a decline in market share for Gilead's established therapies. The company must continue to innovate and develop new drugs to mitigate the impact of generic competition.

Another challenge is the evolving regulatory environment. Changes in healthcare policies, pricing regulations, and reimbursement systems can significantly impact the profitability of pharmaceutical companies. Gilead operates in multiple regions and must navigate various regulatory frameworks, which can introduce uncertainties and challenges to its business operations.

Additionally, Gilead faces intense competition from established pharmaceutical and smaller biotech firms. Rapid technological advancements and evolving treatment paradigms characterize the industry. Competitors may develop new therapies or gain regulatory approvals threatening Gilead's market share. The company must continue to invest in research and development to maintain its competitive edge.

Clinical trial failures and delays are also inherent risks in the biopharmaceutical industry. Despite rigorous research and development processes, there is always a possibility that promising drug candidates may fail to meet efficacy or safety requirements during clinical trials. These setbacks can result in significant financial losses and delays in product launches, impacting Gilead's revenue streams.

Additionally, Gilead faces the challenge of addressing changing treatment landscapes and shifting patient preferences. Medical advancements, scientific discoveries, and evolving disease patterns can alter the demand for specific therapies. Gilead must anticipate and adapt to these changes to ensure its products remain relevant and effective.

Risk management is crucial for Gilead Sciences to mitigate potential challenges. The company employs rigorous clinical trial protocols, invests in diverse therapeutic areas, and pursues strategic partnerships to diversify its product portfolio. Gilead's strong financial position allows it to navigate uncertainties and invest in research and development initiatives. Furthermore, the company monitors regulatory developments and engages with policymakers to shape favorable healthcare policies.

GILD Stock Price History

GILD Stock News Headlines

The asset beating inflation by 4x
Central Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire investors are buying right along with them. Even Warren Buffett put over $500 million into gold. And with the help of a tax and penalty-free "Trump Loophole, " these investors are investing retirement into gold and other precious metals without having to put up any of their own cash. In our Free Precious Metals Guide, we reveal all the details on how the rich use this loophole to protect and growth their retirement wealth in any economy…and show you how you can use it too.
The asset beating inflation by 4x
Central Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire investors are buying right along with them. Even Warren Buffett put over $500 million into gold. And with the help of a tax and penalty-free "Trump Loophole, " these investors are investing retirement into gold and other precious metals without having to put up any of their own cash. In our Free Precious Metals Guide, we reveal all the details on how the rich use this loophole to protect and growth their retirement wealth in any economy…and show you how you can use it too.
Gilead Sciences (NASDAQ:GILD) Sees Large Volume Increase
3 No-Brainer Nasdaq Stocks to Buy in June
3 Dividend Stocks That Even Ken Griffin Is Buying
See More Headlines
Receive GILD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gilead Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 3/28 Dividend
Dividend Payable
Last Earnings
Ex-Dividend for 6/27 Dividend
Dividend Payable
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
17 Analysts


Net Income
$5.67 billion
Pretax Margin


Sales & Book Value

Annual Sales
$27.12 billion
Cash Flow
$8.69 per share
Book Value
$18.26 per share


Outstanding Shares
Free Float
Market Cap
$78.68 billion

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Daniel P. O'Day (Age 60)
    Chairman & CEO
    Comp: $6.99M
  • Mr. Andrew D. DickinsonMr. Andrew D. Dickinson (Age 54)
    Chief Financial Officer
    Comp: $2.66M
  • Ms. Deborah H. Telman (Age 59)
    Executive VP of Corporate Affairs, General Counsel & Corporate Secretary
    Comp: $2.56M
  • Ms. Johanna MercierMs. Johanna Mercier (Age 54)
    Chief Commercial Officer
    Comp: $3.1M
  • Dr. Merdad V. Parsey M.D. (Age 60)
    Ph.D., Chief Medical Officer
    Comp: $2.79M
  • Ms. Sandra Patterson (Age 57)
    Senior VP, Corporate Controller & Principal Accounting Officer
  • Ms. Jacquie Ross C.F.A.
    Vice President of Investor Relations
  • Ms. Jyoti K. Mehra (Age 48)
    Executive Vice President of Human Resources
  • Dr. Linda Slanec Higgins Ph.D. (Age 62)
    Senior Vice President of Research, Innovation & Portfolio
  • Dr. Rudolf Ertl (Age 78)
    Senior Vice President of Commercial Operations of Australia, Canada, Europe

Should I Buy Gilead Sciences Stock? GILD Pros and Cons Explained


Here are some ways that investors could benefit from investing in Gilead Sciences, Inc.:

  • Gilead Sciences, Inc. has recently announced positive results from its latest clinical trials for a groundbreaking antiviral drug, showing great potential for revenue growth and market expansion.
  • The company's strong financial position and consistent revenue streams make it a stable investment option for those seeking long-term growth and stability in their portfolio.
  • Gilead Sciences, Inc. has a diverse pipeline of innovative drugs in various stages of development, reducing the risk associated with dependency on a single product.
  • Recent acquisitions and partnerships have strengthened Gilead Sciences, Inc.'s position in the biopharmaceutical industry, opening up new opportunities for growth and market presence.
  • Analysts have projected a target price increase for Gilead Sciences, Inc. based on its recent performance and strategic initiatives, indicating potential upside for investors.


Investors should be bearish about investing in Gilead Sciences, Inc. for these reasons:

  • The competitive landscape in the biopharmaceutical industry is intense, with increasing regulatory challenges and pricing pressures that could impact Gilead Sciences, Inc.'s profitability.
  • Gilead Sciences, Inc. faces patent expirations on some of its key products in the near future, potentially leading to revenue declines and increased competition from generic alternatives.
  • Market volatility and macroeconomic factors could affect Gilead Sciences, Inc.'s stock price, leading to short-term fluctuations that may deter risk-averse investors.
  • The company's heavy reliance on a few blockbuster drugs for a significant portion of its revenue poses a concentration risk, as any setbacks in these products could impact overall financial performance.
  • Investors should carefully monitor Gilead Sciences, Inc.'s research and development pipeline to ensure continued innovation and product development to sustain long-term growth prospects.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, May 29, 2024. Please send any questions or comments about these Gilead Sciences pros and cons to

GILD Stock Analysis - Frequently Asked Questions

Should I buy or sell Gilead Sciences stock right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last twelve months. There are currently 11 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GILD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GILD, but not buy additional shares or sell existing shares.
View GILD analyst ratings
or view top-rated stocks.

What is Gilead Sciences' stock price target for 2024?

17 brokerages have issued 1 year target prices for Gilead Sciences' shares. Their GILD share price targets range from $69.00 to $105.00. On average, they anticipate the company's stock price to reach $83.69 in the next year. This suggests a possible upside of 32.5% from the stock's current price.
View analysts price targets for GILD
or view top-rated stocks among Wall Street analysts.

How have GILD shares performed in 2024?

Gilead Sciences' stock was trading at $81.01 at the beginning of the year. Since then, GILD shares have decreased by 22.0% and is now trading at $63.15.
View the best growth stocks for 2024 here

Are investors shorting Gilead Sciences?

Gilead Sciences saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 25,430,000 shares, an increase of 17.2% from the May 15th total of 21,700,000 shares. Based on an average daily volume of 7,020,000 shares, the short-interest ratio is currently 3.6 days. Approximately 2.1% of the shares of the company are short sold.
View Gilead Sciences' Short Interest

When is Gilead Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our GILD earnings forecast

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) posted its quarterly earnings results on Thursday, April, 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.49) by $0.17. The biopharmaceutical company had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a trailing twelve-month return on equity of 24.34% and a net margin of 1.76%. The company's revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter last year, the business posted $1.37 EPS.
Read the conference call transcript

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences declared a quarterly dividend on Tuesday, April 23rd. Stockholders of record on Friday, June 14th will be paid a dividend of $0.77 per share on Thursday, June 27th. This represents a $3.08 annualized dividend and a yield of 4.88%. The ex-dividend date of this dividend is Friday, June 14th.
Read our dividend analysis for GILD

Is Gilead Sciences a good dividend stock?

Gilead Sciences (NASDAQ:GILD) pays an annual dividend of $3.08 per share and currently has a dividend yield of 4.73%. GILD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 9 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 855.56%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, GILD will have a dividend payout ratio of 42.60% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GILD.

What guidance has Gilead Sciences issued on next quarter's earnings?

Gilead Sciences issued an update on its FY 2024 earnings guidance on Thursday, April, 25th. The company provided earnings per share (EPS) guidance of 3.450-3.850 for the period, compared to the consensus EPS estimate of 3.670. The company issued revenue guidance of $27.1 billion-$27.5 billion, compared to the consensus revenue estimate of $25.7 billion.

What is Daniel O’Day's approval rating as Gilead Sciences' CEO?

107 employees have rated Gilead Sciences Chief Executive Officer Daniel O’Day on Daniel O’Day has an approval rating of 92% among the company's employees. This puts Daniel O’Day in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.21%), Capital World Investors (6.78%), Capital Research Global Investors (4.92%), Bank of New York Mellon Corp (1.18%), LSV Asset Management (0.46%) and Van ECK Associates Corp (0.45%). Insiders that own company stock include Andrew D Dickinson, Brett A Pletcher, Diane E Wilfong, Diane E Wilfong, Johanna Mercier and Merdad Parsey.
View institutional ownership trends

How do I buy shares of Gilead Sciences?

Shares of GILD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Gilead Sciences have any subsidiaries?
The following companies are subsidiares of Gilead Sciences: Arresto BioSciences, Asegua Therapeutics LLC, CGI Pharmaceuticals, CV Therapeutics, Calistoga Pharmaceuticals, Cell Design Labs, Corus Pharma, Cytopia Pty. Ltd., EpiTherapeutics ApS, Epitherapeutics, Forty Seven, Forty Seven Holdings LLC, Forty Seven Inc., Fosun Pharma Kite Biotechnology Co. Ltd., Gilead Alberta LLC, Gilead Alberta ULC, Gilead Apollo LLC, Gilead Apollo Unlimited Company, Gilead Biopharmaceutics Ireland UC, Gilead Biopharmaceutics US LLC, Gilead Calistoga LLC, Gilead Connecticut Inc., Gilead Holdings LLC, Gilead Ireland Research UC, Gilead Oncology Ireland UC, Gilead Pharmasset LLC, Gilead Sciences (GSR) S.R.L., Gilead Sciences (NZ), Gilead Sciences (Shanghai) Consulting Co. Ltd., Gilead Sciences Americas S. de R.L., Gilead Sciences Argentina S.R.L., Gilead Sciences Belgium BVBA, Gilead Sciences Canada Inc., Gilead Sciences Colombia S.A.S., Gilead Sciences Denmark ApS, Gilead Sciences Europe Limited, Gilead Sciences Farmacêutica do Brasil Ltda., Gilead Sciences Finland Oy, Gilead Sciences GesmbH., Gilead Sciences GmbH, Gilead Sciences Hangzhou Pharmaceutical Co. Ltd., Gilead Sciences Hellas EPE, Gilead Sciences Holding LLC, Gilead Sciences Hong Kong Limited, Gilead Sciences Ilac Ticaret Limited Sirketi, Gilead Sciences India Private Limited, Gilead Sciences International Limited, Gilead Sciences Ireland Unlimited Company, Gilead Sciences Israel Limited, Gilead Sciences KK, Gilead Sciences Korea Limited, Gilead Sciences LLC, Gilead Sciences Lda., Gilead Sciences Limited, Gilead Sciences Luxembourg S.a.r.l., Gilead Sciences Malaysia Sdn. Bhd., Gilead Sciences Mexico S. de R.L. de C.V., Gilead Sciences Netherlands BV, Gilead Sciences Norway AS, Gilead Sciences Poland Sp. z o.o., Gilead Sciences Pty. Ltd., Gilead Sciences Russia LLC, Gilead Sciences S.L., Gilead Sciences S.r.l., Gilead Sciences SAS, Gilead Sciences Shanghai Pharmaceutical Technology Co. Ltd., Gilead Sciences Singapore Pte. Ltd., Gilead Sciences Slovakia s.r.o., Gilead Sciences South Africa (Pty) Ltd., Gilead Sciences Sweden AB, Gilead Sciences Switzerland Sarl, Gilead Sciences YM Australia Pty. Ltd., Gilead Sciences s.r.o., Gilead Therapeutics A1 Unlimited Company, Gilead Therapeutics A2 Unlimited Company, Gilead YM ULC, Immunomedics, Immunomedics Inc., KP EU C.V., Kite Pharma, Kite Pharma EU B.V., Kite Pharma Inc., Kite Pharma LLC, MYR, MYR GmbH, MYR Pharmaceuticals France SAS, Myogen, NeXstar Pharmaceuticals, Nimbus Apollo, Nycomed, Pharmasset, Phenex Pharmaceuticals, Raylo Chemicals, Triangle Pharmaceuticals, YM BioSciences, YM BioSciences Australia Pty. Ltd., and neoKite Inc..
Read More
This page (NASDAQ:GILD) was last updated on 6/19/2024 by Staff

From Our Partners